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Abstract
Background: Primary culture and animal and cell-line models of prostate and bladder development
have limitations in describing human biology, and novel strategies that describe the full spectrum of
differentiation from foetal through to ageing tissue are required. Recent advances in biology
demonstrate that direct reprogramming of somatic cells into pluripotent embryonic stem cell
(ESC)-like cells is possible. These cells, termed induced pluripotent stem cells (iPSCs), could theoreti-
cally generate adult prostate and bladder tissue, providing an alternative strategy to study
differentiation.
Objective: To generate human iPSCs derived from normal, ageing, human prostate (Pro-iPSC), and
urinary tract (UT-iPSC) tissue and to assess their capacity for lineage-directed differentiation.
Design, setting, and participants: Prostate and urinary tract stroma were transduced with POU class
5 homeobox 1 (POU5F1; formerly OCT4), SRY (sex determining region Y)-box 2 (SOX2), Kruppel-like
factor 4 (gut) (KLF4), and v-myc myelocytomatosis viral oncogene homolog (avian) (MYC, formerly
C-MYC) genes to generate iPSCs.
Outcome measurements and statistical analysis: The potential for differentiation into prostate and
bladder lineages was compared with classical skin-derived iPSCs. The student t test was used.
Results and limitations: Successful reprogramming of prostate tissue into Pro-iPSCs and bladder and
ureter into UT-iPSCs was demonstrated by characteristic ESC morphology, marker expression, and
functional pluripotency in generating all three germ-layer lineages. In contrast to conventional skin-
derived iPSCs, Pro-iPSCs showed a vastly increased ability to generate prostate epithelial-speciﬁc
differentiation, as characterised by androgen receptor and prostate-speciﬁc antigen induction. Simi-
larly, UT-iPSCs were shown to be more efﬁcient than skin-derived iPSCs in undergoing bladder
differentiation as demonstrated by expression of urothelial-speciﬁc markers: uroplakins, claudins,
and cytokeratin; and stromal smooth muscle markers: a-smooth-muscle actin, calponin, and desmin.
These disparities are likely to represent epigenetic differences between individual iPSC lines and
highlight the importance of organ-speciﬁc iPSCs for tissue-speciﬁc studies.
Conclusions: IPSCs provide an exciting new model to characterise mechanisms regulating prostate
and bladder differentiation and to develop novel approaches to disease modelling. Regeneration of
bladder cells also provides an exceptional opportunity for translational tissue engineering.
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1. Introduction
Mechanisms involved in prostate and bladder development
and differentiation have been implicated in disease [1–3].
Established animal models of prostate and bladder devel-
opment are well characterised; however, despite providing
key insights for differentiation, there are limitations in
translating these findings to the human setting. Similarly,
there are constraints on studying cells lines that forcibly
maintain expression of immortalising genes. Approaches to
human primary cell culture can overcome some of these
issues, although this can be challenging due to the limited
life-span of cultures, biologic variability between patients,
limited material despite cell expansion, and changes in the
phenotype associated with in vitro culture adaptation
[4–6]. An alternative strategy is the use of embryonic stem
cells (ESCs) that can generate foetal and adult prostate and
bladder tissue [7,8], but this approach is limited by ethics
associated with the source of material. However, a recent
landmark discovery by Yamanaka and colleagues demon-
strated that somatic cells can be reset to an embryonic-like
state, termed induced pluripotent stem cells (iPSCs), by the
expression of defined factors [9,10]. Such cells offer an
unparalleled opportunity for regenerative therapies, dis-
ease modelling, and drug screening [11]. However, iPSCs
appear to retain epigenetic imprinting associated with their
tissue type of origin. This phenomenon results in restricted
terminal differentiation into other cell types [12–14].
In this study, we generated, for the first time, iPSCs
derived from human prostate (Pro-iPSCs) and urinary tract
cells (bladder and ureter) (UT-iPSCs). Furthermore, our data
showed that Pro-iPSCs and UT-iPSCs are more efficient in
differentiating into respective prostate and bladder lineages
relative to established skin fibroblast-derived iPSCs, con-
firming the importance of the organ of origin on the
differentiation potential of the reprogrammed cell.
2. Materials and methods
2.1. Cell culture
All surgical specimens were collected according to local ethical and
regulatory guidelines and included written, informed patient consent
(Freeman Hospital, Newcastle Upon Tyne, UK). Patient details from
which successful iPSC lines were established are summarised in Table 1.
Histologic examination conﬁrmed the absence of dysplasia or malig-
nancy. Prostate primary culture was undertaken according to previously
optimised protocols to separate puriﬁed epithelial and stromal cells
[15,16]. Cell cultures of urothelium and associated urinary tract stroma
were established using a protocol described by Southgate et al. [17].
Detailed protocols for cell culture are provided in Supplement 1. The
homogeneity of the stromal cells that were subsequently transduced
were conﬁrmed by real-time reverse transcription-polymerase chain
reaction (RT-PCR) using a panel of cell lineage markers (CD24 epithelial,
CD45 haematopoietic, von Willebrand factor endothelial, CD146
endothelial, a-smooth-muscle actin [SMA] stromal smooth muscle,
and Thy-1 cell surface antigen [CD90] stromal cells).
2.2. Lentivirus transduction
Pure cultures of 5 104 prostate, bladder, and ureter stromal cells were
transduced using a polycistronic lentiviral vector (POU class 5 homeobox
1 [POU5F1, formerly OCT4], SRY [sex determining region Y]-box 2 [SOX2],
Kruppel-like factor 4 (gut) [KLF4], and v-myc myelocytomatosis viral
oncogene homolog [avian] [MYC, formerly C-MYC]; Allele Biotech, San
Diego, CA, USA) at a multiplicity of infection of 10 in the presence of
polybrene (10 mg/ml) and transductionmedium (RPMI1640mediumwith
HEPESmodiﬁcation; Sigma-Aldrich Co, St. Louis,MO,USA) containing 10%
foetal calf serum (Sigma-Aldrich Co, St. Louis, MO, USA), L-glutamine
(2 mM), and1%penicillinandstreptomycin (InvitrogenCorp,Carlsbad, CA,
USA).Onday2, the transductionmedium(including lentiviralvectors)was
replaced with standard stroma culture medium. On day 6, cells were
seeded onto gelatine-coated plates with a feeder layer of irradiated
CF-1 mouse embryonic ﬁbroblasts (MEFs) (MTI-GlobalStem, Rockville,
MD, USA) in human ESC medium (Knockout Dulbecco’s modiﬁed Eagle’s
medium,1 mML-glutamine,100mMnonessential aminoacids,20%serum
replacement,and8ng/mlﬁbroblastgrowthfactor [FGF]2 [InvitrogenCorp,
Carlsbad, CA, USA]). Additional details on optimisation of these protocols
areavailable inSupplement1.Afteranadditionalweek, cellswerecultured
in MEF-conditioned ESC medium. ESC-like colonies were manually
selected based on morphology between 4 and 6 wk. The medium was
changed every 48 h. A similar protocol was applied to epithelial cells but
was unsuccessful in iPSCs generation; it is described in Supplement 1.
2.3. Characterisations by polymerase chain reaction, DNA
fingerprinting, karyotyping, immunofluorescence, and alkaline
phosphatase staining
RNA isolation and real time RT-PCR was normalised to glyceraldehyde
3-phosphate dehydrogenase according to protocols described in
Supplement 1. DNA ﬁngerprinting was based on microsatellite markers
for short tandem repeats and karyotyping was determined by Giemsa
banding. Details about this and about alkaline phosphatase activity
detection and immunoﬂuorescence are described in Supplement 1.
2.4. Assays of pluripotency
In vitro and in vivo differentiation assays, and embryoid body and
teratoma formation were undertaken using established protocols and
are detailed in Supplement 1.
Table 1 – Details of patients from whom induced pluripotent stem cells lines were established
Patent identiﬁer Age, yr Sex Nature of tissue biopsy
12380 65 Female Ureter biopsy from radical nephrectomy for renal cell carcinoma
12459 66 Male Bladder biopsy from cystoprostatectomy undertaken as part of urinary diversion
for benign functional disorder (secondary to urethral injury and bowel surgery)
12491 48 Male Bladder biopsy from cystoprostatectomy for benign, functional, neurologic
disorder
12502 54 Male Ureter biopsy from radical nephrectomy for renal cell carcinoma
12506 56 Male Bladder biopsy from cystoprostatectomy for benign functional neurologic disorder
11901 66 Male Prostate biopsy from cystoprostatectomy for bladder cancer
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2.5. Lineage-specific differentiation of human induced
pluripotent stem cells in vitro
MEFs were removed for differentiation studies. For the induction of
prostate differentiation, Pro-iPSCs were cultured with primary prostate
stroma-conditioned medium. For bladder differentiation, UT-iPSCs were
culturedwith conditionedmedium for 14d using a previously established
protocol [18]. Details of the conditioned medium from either cultured
human urothelial cells or stroma cells are described in Supplement 1.
Comparison of differentiation potential was drawn against conventional
human-skin iPSCs, which is a pre-established cell line [19].
2.6. Statistical analysis
All results are expressed as mean plus or minus the standard error, and
statistical differences assessed using the student t test with p values
0.05 considered signiﬁcant.
3. Results
3.1. Generation of induced pluripotent stem cells from normal
ageing prostate and human urinary tract cells
Once primary cultures of prostate, bladder, and ureter
stromal cells were established, we examined the purity of
fibroblast lineage. Following passage, there was an inherent
culture-based selection for fibroblasts based on cell mor-
phology and lineage-marker expressions. Morphologically,
cells were consistent with primary, prostate stromal fibro-
blasts and were confirmed to be devoid of endothelial,
epithelial, and haematopoietic contamination following the
first passage (Supplemental Fig. S1A and S1B). Pure bladder
and ureter stromal cells expressing smooth muscle and[(Fig._1)TD$FIG]
Fig. 1 – (A) Timeline for induced pluripotent stem cell (iPSC) generation. (B) Example of established iPSC colonies growing on a feeder layer with human
embryonic stem cell (ESC)–like morphology. (C) Immunofluorescence of generated iPSCs for the expression of specific human ESC surface markers: stage-
specific embryonic antigen-4 (SSEA4), tumour rejection antigen (TRA)-1-81, TRA-1-60, and nuclear transcription factors Nanog homeobox (NANOG) and
POU class 5 homeobox 1(POU5F1, formerly OCT4). Note mouse embryonic fibroblast (MEF) cells at the periphery of the colonies are negative for stem cell
marker expression. Nuclei were stained with 40 ,6-diamidino-2-phenylindole (blue) (scale bar = 100 mm), and specific cellular localisation of the stem cell
markers are shown in their expected distribution.
hESC = human embryonic stem cell; Pro-iPSC = prostate induced pluripotent stem cell; UT-iPSC = urinary tract induced pluripotent stem cell.
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myofibroblastic markers a-SMA and CD90 were confirmed
at second passage, associated with typical stromal-cell
appearance (Supplemental Fig. S2A and S2B). Polycistronic
lentiviral vectors containing the four transcription factors
POU5F1, SOX2, KLF4, and MYC were transduced into pure
stromal cells. A schedule for human iPSC reprogramming is
summarised in Figure 1A. Seven days following lentiviral
transduction, fibroblasts demonstrated features of mesen-
chymal to epithelial transition, which is typical of early
reprogramming [20]. Mesenchymal to epithelial transition
was characterised by a change in the prostate fibroblast
morphology from spindle-shaped cells to classic, epitheloid,
cobblestone colonies, and was confirmed by marker expres-
sion showing upregulation of epithelial marker E-cadherin
and downregulation ofmesenchymalmarkers snail homolog
1 and 2 (Drosophila) (dubbed Snail and Slug, respectively)
(p < 0.05) (Supplemental Fig. S1C). Four week to 5 wk after
transduction with the lentivirus, several small and tight cell
colonies were detected; however, they grew slowly and so
were not consistent with ESC-like cells (Supplemental
Fig. S2C). By week 6 after transduction, rapidly growing
colonies displaying morphology similar to that of human
ESCs were observed (tight and flat colonies with clear-cut
edges composed of small cells with a high nucleus-
to-cytoplasm ratio) (Fig. 1B, Supplemental Fig. S1D and
S2D). Eleven prostate and 31 urinary tract ESC-like colonies
(17 bladder and 14 ureter) were successfully expanded and
stably maintained throughout culture passages (>50 pas-
sages,>10mo). Theoverall efficiency ingeneratingPro-iPSCs
and UT-iPSCs was low (0.02–0.04% of all stromal cells
transfected),butwas comparable to the reportedefficiencyof
iPSCs generated from human dermal fibroblasts [21].
Karyotyping confirmed a diploid 46,XY chromosome
arrangement (Supplemental Fig. S1E and S2E). Authentica-
tion of Pro-iPSCs and UT-iPSCs derivation from parental
stromal cells was confirmed using DNA fingerprinting
(Supplemental Fig. S1F and S2F).
3.2. Characterisation of generated induced pluripotent stem
cells
Immunofluorescence for human, ESC-specific, surface
markers—stage-specific embryonic antigen-4, tumour
rejection antigen (TRA)-1-81, and TRA-1-60, and also
[(Fig._2)TD$FIG]
Fig. 2 – (A) Alkaline phosphatase staining of induced pluripotent stem cell (iPSC) colonies. Note underlying mouse embryonic fibroblast cells act as
negative control cells with no staining. (B) Reverse transcription–polymerase chain reaction (RT-PCR) analysis demonstrating silencing of exogenous
transgene expression in iPSCs. Control represents stromal cells 6 d after transduction. (C) Real-time RT-PCR analysis for expression of endogenous POU
class 5 homeobox 1 (POU5F1, formerly OCT4), SRY (sex determining region Y)-box 2 (SOX2), and other stem cell marker genes: Nanog homeobox (NANOG),
growth differentiation factor 3 (GDF3), DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) and ZFP42 zinc finger protein (ZFP42, formerly REX1) in
iPSCs. All values were calculated with respect to the value for H9 human embryonic stem cell, which was set to 1.
Pro-iPSC = prostate induced pluripotent stem cell; UT-iPSC = urinary tract induced pluripotent stem cell; ENDO = endothelial.
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transcription factors Nanog homeobox (NANOG) and
POU5F1—was confirmed (Fig. 1C). Additionally, alkaline
phosphatase activity, typical of an ESC phenotype, was
demonstrated in the induced cells (Fig. 2A). Exogenous
transgenesilencing isassociatedwith thegenerationof iPSCs,
where there is a critical switch to endogenous expression of
key ESC regulatory factors such as POU5F1, SOX2, andNANOG.
Real-time RT-PCR using primers specific for lentiviral
transcripts demonstrated that exogenous transgene expres-
sionhad ceased inboth Pro-iPSC andUT-iPSC clones (Fig. 2B).
Furthermore, endogenous expression of the pluripotency
markers POU5F1, SOX2, and NANOG, in addition to ESC
markers growth differentiation factor 3 (GDF3), DNA (cyto-
sine-5-)-methyltransferase 3 beta (DNMT3B), and ZFP42 zinc
finger protein (ZFP42, formerly REX1) in both Pro-iPSCs and
UT-iPSCswas consistentwith expression levels in the control
human-ESC lineH9(Fig. 2C). The iPSCcloneswere identical in
terms of ESC-like morphology, proliferation, and gene-
expression signatures (data not shown).
3.3. Pluripotency of generated induced pluripotent stem cells
When cultured in suspension on low-adhesion plates in the
absence of basic FGF, both Pro-iPSCs and UT-iPSCs formed
embryoid bodies containing all three germ-layer deriva-
tives, as demonstrated by immunofluorescence of lineage-
specific markers bIII tubulin (ectoderm), CD31 (mesoderm),
anda-fetoprotein (endoderm) (Fig. 3A). Xenografts from the
in vivo teratoma-forming assay also confirmed ectoderm,
mesoderm, and endoderm lineage histology (Fig. 3B).
3.4. Prostate induced pluripotent stem cells differentiate into
androgen receptor and prostate-specific antigen–expressing cells
Wecompared the differentiation potential of Pro-iPSCswith
conventional skin-derived iPSCs (skin-iPSCs). Following
induced differentiation by prostate stromal-cell condi-
tioned medium for 3 wk, both Pro-iPSCs and skin-iPSCs
displayed epithelioid cell morphology. Transcripts of
epithelial marker CD24 were detected at comparable levels
to primary prostate epithelium (data not shown). When
characterised with the prostate differentiation markers
androgen receptor (AR) and prostate-specific antigen (PSA),
the prostate-specific phenotype was restricted to Pro-iPSCs
(Fig. 4). AR expressionwas present in the differentiated Pro-
iPSCs and the degree of immunofluorescence was at levels
comparable with mature prostate epithelium in early
primary culture (day 10), whereas only minimal levels of
AR were detected in skin-iPSCs (Fig. 4A). Functional AR was
confirmed by PSA transcript and protein expression at levels
in keeping with primary, cultured, prostate epithelia,
whereas no PSA expression was detected in the differentia-
tion medium-treated skin-iPSCs (Fig. 4B).
3.5. Urinary tract-induced pluripotent stem cells differentiate
into uroplakin-expressing cells
Lineage-specific differentiation of the UT-iPSCs into bladder
lineages was assessed using established coculture methods
[18]. In comparison to cells derived from skin-iPSCs, UT-
iPSCs were significantly more efficient at inducing bladder-
specific differentiation, as demonstrated by urothelial
differentiation-specific genes (UPIb, UPII, UPIIIa, and UPIIIb;
claudin 1 [CLD1], claudin 5 [CLD5] and keratin 7 [CK7]) and
markers specific for smooth-muscle cells (a-SMA, calponin,
and desmin) (Fig. 5A). Furthermore, the effect of condi-
tioned medium from urothelia was compared with that of
conditioned medium from stromal cells (Fig. 5B). Similar to
the embryogenesis of the urinary tract, where there is a
reciprocal differentiation of epithelial and mesenchymal
fractions [22], both urothelial and stromal differentiation
was concurrently induced using either urothelial- or
stromal-conditioned medium (Fig. 5A and 5B). UPIb protein
[(Fig._3)TD$FIG]
Fig. 3 – Pluripotency in prostate induced pluripotent stem cells
(Pro-iPSCs) and urinary tract induced pluripotent stem cells (UT-iPSCs).
(A) Immunofluorescence analysis of embyroid bodies derived from iPSCs
shows expression of the lineage markers bIII-tubulin (ectodermal
marker; red), CD31 (mesodermal marker; green), and a-fetoprotein
(endodermal marker). Nuclei were counterstained with 40 ,6-diamidino-
2-phenylindole (blue) (scale bar = 100 mm). (B) Left: Histologic section of
teratoma formed from Pro-iPSCs showing neuronal epithelial
differentiation. Right: UT-iPSCs representing all three embryonic germ
layers: ectoderm (neuronal rosette-like structures), mesoderm (muscle-
like tissue), and endoderm (intestinal epithelial-like cells).
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expression indicated by immunofluorescence was also
confirmed in differentiated cells derived from UT-iPSCs
after 2 wk in urothelial-conditioned medium (Fig. 5C).
4. Discussion
We report for the first time successful reprogramming of
normal, human, ageing prostate, bladder, and ureter
stromal fibroblasts to an ESC-like pluripotent state. These
cells were validated as de facto iPSCs by confirming their
ability for sustained self renewal, silencing of exogenous
transgenes, expression of ESC-specific genes, and pluripo-
tent differentiation into all three germ lineages. Further-
more, within the appropriate inductive environment,
prostate epithelial-specific differentiation with induced
functional AR, as characterised by PSA expression, was
demonstrated and UT-iPSC differentiation could be directed
into urothelial-specific lineages. These models allow for
enormous scope in future studies of differentiation, tissue
engineering, disease mechanisms, and drug development.
Since the first descriptions of iPSCs in 2006, most reports
have focused on the generation of iPSCs from a range of
normal and diseased tissues. In our work, we generated
multiple clones of UT-iPSCs from multiple donors and sites
(bladder and ureter), and multiple clones of Pro-iPSCs
from a single donor. All clones were comparable to both
skin-iPSCs and ESCs in terms of ESC-marker expression and
pluripotency potential, supporting the generalisability of
these methods to urologic tissues. Researchers exploring
further differences in ability for terminal organ-specific
differentiation among the iPSC lines derived from different
organs have found that not all iPSCs are the same in this
respect [13]. We compared the differentiation potential of
Pro-iPSCs and UT-iPSCs with skin-iPSCs and our results
demonstrated vast differences in their capabilities for
prostate- and bladder-specific differentiation. These find-
ings are consistent with emerging evidence that epigenetic
imprinting, specific to the tissue type of iPSC origin, remains
intact throughout the mechanism of stem cell reprogram-
ming and may limit the potential for terminal differentia-
tion into all cell types [12–14]. Our data emphasise the
importance of the source fromwhich iPSCs are generated as
a consideration for organ-specific development studies.
Although we confirmed prostate-specific differentiation,
additional work is required to determine whether Pro-iPSCs
can generate the full breadth of epithelial differentiation. In
addition, it would be of interest to investigate if these cells
differentiate through somatic stem cell phenotypes or
directly into basal and luminal cells, in keeping with an
alternative model that proposes that epithelial stem cells
[(Fig._4)TD$FIG]
Fig. 4 – Prostate-specific differentiation of prostate induced pluripotent stem cells (Pro-iPSCs). (A) Relative messenger RNA (mRNA) expression of androgen
receptor (AR) in Pro-iPSCs before and after differentiation (control levels in primary prostate stroma and epithelia shown) (n = 6). Right:
Immunofluorescence staining for AR (green) shown in Pro-iPSCs and skin-iPSCs. AR is induced in Pro-iPSCs only, with functional activity suggested by
nuclear AR localisations (blue 40 ,6-diamidino-2-phenylindole [DAPI] counterstain). (B) Relative mRNA expression of prostate-specific antigen (PSA) in
Pro-iPSCs before and after differentiation (control levels in primary prostate stroma and epithelia shown) (n = 3). Immunofluorescence staining for PSA
(green) shown in Pro-iPSCs and skin-iPSCs. PSA is induced in Pro-iPSCs only (blue DAPI counterstain).
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maintain thephenotypeof the original embryonicprogenitor
of the prostate (urogenital sinus epithelium) [23]. Also of
interest would be further in vivo study of prostate epithelial
development and organisation from iPSCs, especially given
the considerable debate about the nature of the somatic stem
cell in prostate epithelium. Recent evidence has shown that
in early, postnatal, mouse prostate development, epithelial
homeostasis is maintained by basal multipotent stem cells
that differentiate into basal, luminal, and neuroendocrine
cells, as well as by unipotent basal and luminal progenitors
[24]. In contrast, in situ assays in the human adult setting
have revealed that epithelial hierarchical organisation is
basedona commonstemcell [25]. ThePro-iPSCmodel iswell
placed to explore these differences with lineage tracking
studies. Furthermore, the generation of ESC-like Pro-iPSCs
are of particular interest to the study of prostate disease,
where benign prostatic hyperplasia has been associatedwith
models of embryonic reawakening [26] and prostate cancer
can be associated with ESC-marker expressions [27].
Atala and colleagues reported the first humanclinical trial
with engraftment of both urothelial and smooth-muscle
stromal cells into acellular biomaterials for bladder engi-
neering and reconstruction [28]. However, these strategies
rely on ex vivo cell culture to generate sufficient quantities
and quality of autologous cells. Although even small biopsies
of normal urothelium can be readily expanded before
undergoing senescence, this is significantly restricted in
diseased tissue [29]. We were unsuccessful in preliminary
[(Fig._5)TD$FIG]
Fig. 5 – Expression of urothelial and smooth-muscle lineage-specific transcripts in differentiated cells derived from urinary tract induced pluripotent stem
cells (UT-iPSCs) and skin-iPSCs by reverse transcription-polymerase chain reaction on day 14. Messenger RNA levels are shown as a fold change relative to
control (undifferentiated cells) (n = 3). (A) Expression of urothelial-specific markers (UPIb, UPII, UPIIIa, UPIIIb, claudin 1 [CLD1], claudin 5 [CLD5], keratin
7 [CK7]) and smooth-muscle-specific markers (a-smooth muscle actin [a-SMA], calponin, desmin) induced with conditioned medium from urothelium.
(B) Expression of urothelial- and smooth-muscle–specific markers induced with conditioned medium from stroma. (C) Immunofluorescence of
differentiated cells derived from UT-iPSCs treated with conditioned medium, at day 14, showing (left) bright field; (centre) positive staining for UPIb (red)
juxtaposed with an area of UPIb-negative staining, with 40 ,6-diamidino-2-phenylindole nuclear counterstain (blue); and high magnification of UPIb
immunostaining (scale bar = 100 mm).
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attempts at inducing urothelium. Further experimentation
was not pursued given that the stroma-based UT-iPSCs
demonstrated ability to differentiate into urothelium. In
clinical applications for regenerativemedicine, this phenom-
enon also provides the additional attraction of using an
alternative, genetically normal tissue source in urothelial
malignancies for reconstruction. However, concerns about
induction of malignancies from iPSCs persist and are being
cautiously tackled with refinements in induction methods
that include virus-free and transgene-free reprogramming
and xeno-free approaches [30]. Alternative approaches are
nowbecoming established to realise this ambition, including
vector-free human-iPSC generation using episomal-factor
delivery, and feeder-free and albumin-free culture [31]. As
such, UT-iPSCs show great promise in clinical regenerative
medicine and modelling urinary tract disease.
5. Conclusions
Human prostate and urinary tract tissue can be used to
generate iPSCs that can be differentiated back into their
parent organ lineages. The generation of Pro-iPSCs and
UT-iPSCs provides a convenient ready-to-access model that
offers considerable potential for studies of normal and
diseased prostate and bladder biology.
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